Latest News

  • Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences Read More
  • Alkermes Announces Initiation of Phase 1 Clinical Study of New CNS Drug Candidate ALKS 7119 Read More
  • Alkermes Announces Topline Results of FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 in Major Depressive Disorder Read More

Investors

Learn More

Working at Alkermes

Join Our Team